NDASUBCUTANEOUSEMULSION
Approved
Aug 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
3/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CAMCEVI is a subcutaneous leuprolide mesylate emulsion approved by the FDA on August 25, 2025, representing a new formulation of the established GnRH agonist leuprolide. The drug treats hormone-responsive cancers and endometriosis by suppressing gonadotropin and sex hormone secretion. As a reformulation of a well-known mechanism, CAMCEVI offers an alternative delivery profile to existing leuprolide products.
Growth12.3 years to LOE
Early growth stage with zero competitive pressure creates opportunity for market share capture and rapid team expansion in sales and marketing.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty
Started Jun 2023
94 enrolled
Puberty; Precocious, Central
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate (LMIS 25 mg) in Subjects With Prostate Cancer
Started Sep 2017
144 enrolled
Prostatic Neoplasms
Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma
Started Aug 2014
137 enrolled
Prostatic Neoplasms
Career Relevance
CAMCEVI launch creates immediate career opportunities in a newly approved product with zero competitive pressure and 12+ years of exclusivity. This is an ideal position for brand-building roles and establishing market leadership in oncology and specialty care.
Worked on CAMCEVI ETM at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.